Superficial thrombophlebitis, unjustly underestimated disease – has the time come to change our view?

Česká verzia

Authors: J. Hirmerová
Authors place of work: II. interní klinika Lékařské fakulty UK a FN Plzeň, přednosta prof. MUDr. Jan Filipovský, CSc.
Published in the journal: Vnitř Lék 2012; 58(9): 647-653
Category: Reviews

Summary

Superficial thrombophlebites represent a very heterogeneous group of diseases which is caused by the difference between two basic forms of ST – varicophlebitis and thrombophlebitis of a “healthy” vein, as well as by other factors – the ratio of thrombotic and inflammatory process, the location and extent of thrombosis in superficial venous system, the distance from deep venous system, the stage of venous insufficiency and the general thrombotic risk of a patient. ST shares many common features with deep vein thrombosis (clinical risk factors, thrombophilic disorders), both diseases often coincide or follow one another. Some authors suggest considering ST as a part of venous thromboembolism in a broader sense. There are ensuing unresolved questions regarding ST management. So far, no evidence-based treatment has been clearly defined. Anticoagulation is recommended in more serious cases but no consensus about dosing and duration has been reached. The CALISTO trial confirmed a benefit of fondaparinux in prophylactic dose in the therapy of isolated ST and the results have been reflected in recent guidelines of expert groups. Further studies to improve our knowledge of ST and to earn more evidence about its management are definitely needed.

Key words:
superficial thrombophlebitis – deep vein thrombosis – thrombophilic disorders – anticoagulation therapy

Zdroje

1. Hingorani A, Ascher E. Superficial venous thrombophlebitis. In: Handbook of Venous Disorders. 3rd Ed. London, UK: Hodder Arnold 2009: 314–319.

2. Kitchens CS. How I treat superficial venous thrombosis. Blood 2011; 117: 39–44.

3. Blättler W, Schwarzenbach B, Largiadèr J. Superficial vein thrombophlebitis – serious concern or much ado about little? Vasa2008; 37: 31–38.

4. Schellong S, Schwarz T. Phlebitis. Peripheral Venous Diseases: Nonsurgical Approach. In: Lanzer P, Topol EJ (eds). PanVascular Medicine. Berlin Heidelberg, Germany: Springer-Verlag 2002: 1505–1506.

5. Leon L, Giannoukas AD, Dodd D et al. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg 2005; 29: 10–17.

6. Haire WD. Deep Venous Thrombosis and Pulmonary Embolus. In: Kitchens, Alving, Kessler. Consultative Hemostasis and Thrombosis. Elsevier Science 2002: 211–212.

7. Perrin M, Gillet JL. A review of superficial thrombophlebitis of the lower limbs. Phlebolymphology 2002; 38: 69–73.

8. Litzendorf MA, Satiani B. Superficial venous thrombosis: disease progression and evolving treatment approaches. Vasc Health Risk Manag 2011; 7: 569–575.

9. McColl MD, Ramsay JE, Tait RC et al. Superficial vein thrombosis: incidence in association with pregnancy and prevalence of thrombophilic defects. Thromb Haemost 1998; 79: 741–742.

10. deSancho MT, Dorff T, Rand JH. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy. Blood Coagul Fibrinolysis 2010; 21: 534–538.

11. de Moerloose P, Wutschert R, Heinzmann M et al. Superficial vein thrombosis of lower limbs: influence of factor V Leiden, factor II G20210A and overweight. Thromb Haemost 1998; 80: 239–241.

12. Trousseau A. Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris 1865; 5: 281–332.

13. Mouton WG, Kienle Y, Muggli B et al. Tumors associated with superficial thrombophlebitis. Vasa 2009; 38: 167–170.

14. Leon LR Jr, Labropoulos N. Superficial vein thrombosis and hypercoagulable states: the evidence. Perspect Vasc Surg Endovasc Ther 2005; 17: 43–46.

15. Wichers IM, Haighton M, Büller HR et al. A retrospective analysis of patients treated for superficial vein thrombosis. Neth J Med 2008; 66: 423–427.

16. Sørensen HT, Sværke C, Farkas DK et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer 2012; 48: 586–593.

17. Karathanos C, Sfyroeras G, Drakou A et al. Superficial vein thrombosis in patients with varicose veins: role of thrombophilia factors, age and body mass. Eur J Vasc Endovasc Surg 2012; 43: 355–358.

18. Milio G, Siragusa S, Minà C et al. Superficial venous thrombosis: prevalence of common genetic risk factors and their role on spreading to deep veins. Thromb Res 2008; 123: 194–199.

19. Hanson JN, Ascher E, DePippo P et al. Saphenous vein thrombophlebitis (SVT): a deceptively benign disease. J Vasc Surg 1998; 27: 677–680.

20. Martinelli I, Cattaneo M, Taioli E et al. Genetic risk factors for superficial vein thrombosis. Thromb Haemost 1999; 82: 1215–1217.

21. Schönauer V, Kyrle PA, Weltermann A et al. Superficial thrombophlebitis and risk for recurrent venous thromboembolism. J Vasc Surg 2003; 37: 834–838.

22. de Godoy JM, Batigália F, Braile DM. Superficial thrombophlebitis and anticardiolipin antibodies – report of association. Angiology 2001; 52: 127–129.

23. de Godoy JM, Braile DM. Protein S deficiency in repetitive superficial thrombophlebitis. Clin Appl Thromb Hemost 2003; 9: 61–62.

24. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742–748.

25. Decousus H, Quéré I, Presles E et al. POST (ProspectiveObservational Superficial Thrombophlebitis) Study Group. Superficial Venous Thrombosis and Venous Thromboembolism. A Large, Prospective Epidemiologic Study. Ann Intern Med 2010; 152: 218–224.

26. Galanaud JP, Genty C, Sevestre MA et al. OPTIMEV SFMV investigators. Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis. The OPTIMEV study. Thromb Haemost 2011; 105: 31–39.

27. Blumenberg RM, Barton E, Gelfand ML et al. Occult deep venous thrombosis complicating superficial thrombophlebitis. J Vasc Surg 1998; 27: 338–343.

28. Bounameaux H, Reber-Wasem MA. Superficial thrombophlebitis and deep vein thrombosis. A controversial association. Arch Intern Med 1997; 157: 1822–1824.

29. Pulliam CW, Barr SL, Ewing AB. Venous duplex scanning in the diagnosis and treatment of progressive superficial thrombophlebitis. Ann Vasc Surg 1991; 5: 190–195.

30. Chengelis DL, Bendick PJ, Glover JL et al. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 1996; 24: 745–749.

31. Heit JA, Silverstein MD, Mohr DN et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809–815.

32. Tosetto A, Frezzato M, Rodeghiero F. Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA Project. J Thromb Haemost 2003; 1: 1724–1729.

33. Decousus H, Leizorovicz A. Superficial thrombophlebitis of the legs: still a lot to learn. J Thromb Haemost 2005; 3: 1149–1151.

34. Vítovec M, Pecháček V. Doporučení pro duplexní ultrazvukové vyšetření končetinových žil. Vnitř Lék 2009; 55: 136–146.

35. Décousus H, Bertoletti L, Frappé P et al. Recent findings in the epidemiology, diagnosis and treatment of superficial-vein thrombosis. Thromb Res 2011; 127 (Suppl 3): S81–S85.

36. Titon JP, Auger D, Grange P et al. Traitement curatif des thromboses veineuses superficielles par nadroparine calcique. Recherche posologique et comparaison à un anti-inflammatoire non stéroïdien. Ann Cardiol Angeiol (Paris) 1994; 43: 160–166.

37. Belcaro G, Nicolaides AN, Errichi BM et al. Superficial thrombophlebitis of the legs: a randomized, controlled, follow-up study. Angiology 1999; 50: 523–529.

38. Marchiori A, Verlato F, Sabbion P et al. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica 2002; 87: 523–527.

39. Lozano FS, Almazan A. Low-molecular-weight heparin versus saphenofemoral disconnection for the treatment of above-knee greater saphenous thrombophlebitis: a prospective study. Vasc Endovascular Surg 2003; 37: 415–420.

40. Superficial Thrombophlebitis Treated By Enoxaparin Study Group. A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003; 163: 1657–1663.

41. Prandoni P, Tormene D, Pesavento R. Vesalio Investigators Group. High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost 2005; 3: 1152–1157.

42. Decousus H, Prandoni P, Mismetti P et al. CALISTO Study Group. Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. N Engl J Med 2010; 363: 1222–1232.

43. Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2007; 2: CD004982.

44. Kearon C, Kahn SR, Agnelli G et al. American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest 2008; 133 (6 Suppl): 454S–545S.

45. Štvrtinová V, Dukát A, Frankovičová M et al. Povrchová tromboflebitída – diagnostika a liečba. Vnitř Lék 2009; 55: 131–135.

46. Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev 2012; 3: CD004982.

47. Kearon C, Akl EA, Comerota AJ et al. AmericanCollege of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis (9^th Ed): American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S–e494S.

48. Goldman L, Ginsberg J. Superficial phlebitis and phase 3.5 trials. N Engl J Med 2010; 363: 1278–1280.

49. Blondon M, Righini M, Bounameaux H et al. Fondaparinux for isolated superficial-vein thrombosis of the legs: a cost-effectiveness analysis. Chest 2012; 141: 321–329.

50. Carnero-Vidal LG, Rathbun S, Wakefield TW. Anticoagulant treatment for superficial venous thrombosis. Dis Mon 2010; 56: 574–581.

51. Dalsing MC. The case against anticoagulation for superficial venous thrombosis. Dis Mon 2010; 56: 582–589.

52. Galanaud JP, Bosson JL, Genty C. Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies. J Thromb Haemost 2012; doi: 10.1111/j.1538-7836.2012.04704.x. (Epub ahead of print).

53. Souto JC, Almasy L, Borrell M et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia. Am J Hum Genet 2000; 67: 1452–1459.

54. Severinsen MT, Overvad K, Johnsen SP et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol 2010; 149: 273–279.